vs
Amphastar Pharmaceuticals, Inc.（AMPH）とPROVIDENT FINANCIAL SERVICES INC（PFS）の財務データ比較。上の社名をクリックして会社を切り替えられます
PROVIDENT FINANCIAL SERVICES INCの直近四半期売上が大きい（$225.7M vs $183.1M、Amphastar Pharmaceuticals, Inc.の約1.2倍）。PROVIDENT FINANCIAL SERVICES INCの前年同期比売上増加率が高い（9.6% vs -1.8%）。PROVIDENT FINANCIAL SERVICES INCの直近四半期フリーキャッシュフローが多い（$430.7M vs $24.6M）。過去8四半期でPROVIDENT FINANCIAL SERVICES INCの売上複合成長率が高い（40.4% vs 3.2%）
Amphastar Pharmaceuticalsは上場されている米国の特殊製薬企業です。2004年5月に設立され、主に吸入剤および鼻腔内投与製品の開発、生産、販売を行っており、特色ある医薬品分野で事業を展開しています。
PNCフィナンシャル・サービシズ・グループは、ペンシルベニア州ピッツバーグに本社を置く米国の銀行持株会社・金融サービス企業です。傘下のPNC銀行は全米27州とワシントンD.C.で事業を展開し、2629の支店と9523台のATMを運営しており、資産規模・支店数・預金残高・ATM台数いずれにおいても米国有数の銀行です。
AMPH vs PFS — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $183.1M | $225.7M |
| 純利益 | $24.4M | — |
| 粗利率 | 46.8% | — |
| 営業利益率 | 19.4% | 49.7% |
| 純利益率 | 13.3% | — |
| 売上前年比 | -1.8% | 9.6% |
| 純利益前年比 | -35.7% | — |
| EPS（希薄化後） | $0.51 | $0.64 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $183.1M | $225.7M | ||
| Q3 25 | $191.8M | $221.8M | ||
| Q2 25 | $174.4M | $214.2M | ||
| Q1 25 | $170.5M | $208.8M | ||
| Q4 24 | $186.5M | $205.9M | ||
| Q3 24 | $191.2M | $210.6M | ||
| Q2 24 | $182.4M | $163.8M | ||
| Q1 24 | $171.8M | $114.5M |
| Q4 25 | $24.4M | — | ||
| Q3 25 | $17.4M | $71.7M | ||
| Q2 25 | $31.0M | $72.0M | ||
| Q1 25 | $25.3M | $64.0M | ||
| Q4 24 | $38.0M | — | ||
| Q3 24 | $40.4M | $46.4M | ||
| Q2 24 | $37.9M | $-11.5M | ||
| Q1 24 | $43.2M | $32.1M |
| Q4 25 | 46.8% | — | ||
| Q3 25 | 51.4% | — | ||
| Q2 25 | 49.6% | — | ||
| Q1 25 | 50.0% | — | ||
| Q4 24 | 46.5% | — | ||
| Q3 24 | 53.3% | — | ||
| Q2 24 | 52.2% | — | ||
| Q1 24 | 52.4% | — |
| Q4 25 | 19.4% | 49.7% | ||
| Q3 25 | 13.2% | 45.8% | ||
| Q2 25 | 24.2% | 47.8% | ||
| Q1 25 | 21.9% | 44.0% | ||
| Q4 24 | 24.2% | 30.5% | ||
| Q3 24 | 29.8% | 31.0% | ||
| Q2 24 | 30.3% | -13.0% | ||
| Q1 24 | 27.9% | 37.5% |
| Q4 25 | 13.3% | — | ||
| Q3 25 | 9.0% | 32.3% | ||
| Q2 25 | 17.8% | 33.6% | ||
| Q1 25 | 14.8% | 30.7% | ||
| Q4 24 | 20.4% | — | ||
| Q3 24 | 21.1% | 22.0% | ||
| Q2 24 | 20.8% | -7.0% | ||
| Q1 24 | 25.1% | 28.0% |
| Q4 25 | $0.51 | $0.64 | ||
| Q3 25 | $0.37 | $0.55 | ||
| Q2 25 | $0.64 | $0.55 | ||
| Q1 25 | $0.51 | $0.49 | ||
| Q4 24 | $0.74 | $0.37 | ||
| Q3 24 | $0.78 | $0.36 | ||
| Q2 24 | $0.73 | $-0.11 | ||
| Q1 24 | $0.81 | $0.43 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $282.8M | $209.1M |
| 総負債低いほど良い | $608.7M | — |
| 株主資本純資産 | $788.8M | $2.8B |
| 総資産 | $1.6B | $25.0B |
| 負債/資本比率低いほどレバレッジが低い | 0.77× | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $282.8M | $209.1M | ||
| Q3 25 | $276.2M | $299.2M | ||
| Q2 25 | $231.8M | $258.0M | ||
| Q1 25 | $236.9M | $234.1M | ||
| Q4 24 | $221.6M | $205.9M | ||
| Q3 24 | $250.5M | $244.0M | ||
| Q2 24 | $217.8M | $290.5M | ||
| Q1 24 | $289.6M | $158.3M |
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
| Q4 25 | $788.8M | $2.8B | ||
| Q3 25 | $776.7M | $2.8B | ||
| Q2 25 | $757.5M | $2.7B | ||
| Q1 25 | $751.3M | $2.7B | ||
| Q4 24 | $732.3M | $2.6B | ||
| Q3 24 | $727.7M | $2.6B | ||
| Q2 24 | $713.3M | $2.6B | ||
| Q1 24 | $672.4M | $1.7B |
| Q4 25 | $1.6B | $25.0B | ||
| Q3 25 | $1.7B | $24.8B | ||
| Q2 25 | $1.6B | $24.5B | ||
| Q1 25 | $1.6B | $24.2B | ||
| Q4 24 | $1.6B | $24.1B | ||
| Q3 24 | $1.5B | $24.0B | ||
| Q2 24 | $1.5B | $24.1B | ||
| Q1 24 | $1.6B | $14.1B |
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $32.9M | $442.3M |
| フリーキャッシュフロー営業CF - 設備投資 | $24.6M | $430.7M |
| FCFマージンFCF / 売上 | 13.4% | 190.8% |
| 設備投資強度設備投資 / 売上 | 4.5% | 5.1% |
| キャッシュ転換率営業CF / 純利益 | 1.35× | — |
| 直近12ヶ月FCF直近4四半期 | $121.2M | $797.4M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $32.9M | $442.3M | ||
| Q3 25 | $52.6M | $98.0M | ||
| Q2 25 | $35.6M | $186.8M | ||
| Q1 25 | $35.1M | $88.5M | ||
| Q4 24 | $29.0M | $426.4M | ||
| Q3 24 | $60.0M | $69.2M | ||
| Q2 24 | $69.1M | $76.5M | ||
| Q1 24 | $55.3M | $41.4M |
| Q4 25 | $24.6M | $430.7M | ||
| Q3 25 | $47.2M | $96.7M | ||
| Q2 25 | $25.0M | $182.6M | ||
| Q1 25 | $24.4M | $87.4M | ||
| Q4 24 | $16.6M | $425.1M | ||
| Q3 24 | $46.2M | $67.9M | ||
| Q2 24 | $63.1M | $75.5M | ||
| Q1 24 | $46.5M | $40.9M |
| Q4 25 | 13.4% | 190.8% | ||
| Q3 25 | 24.6% | 43.6% | ||
| Q2 25 | 14.3% | 85.2% | ||
| Q1 25 | 14.3% | 41.9% | ||
| Q4 24 | 8.9% | 206.4% | ||
| Q3 24 | 24.1% | 32.2% | ||
| Q2 24 | 34.6% | 46.1% | ||
| Q1 24 | 27.1% | 35.7% |
| Q4 25 | 4.5% | 5.1% | ||
| Q3 25 | 2.8% | 0.6% | ||
| Q2 25 | 6.1% | 2.0% | ||
| Q1 25 | 6.3% | 0.5% | ||
| Q4 24 | 6.7% | 0.6% | ||
| Q3 24 | 7.2% | 0.6% | ||
| Q2 24 | 3.3% | 0.6% | ||
| Q1 24 | 5.1% | 0.5% |
| Q4 25 | 1.35× | — | ||
| Q3 25 | 3.03× | 1.37× | ||
| Q2 25 | 1.15× | 2.59× | ||
| Q1 25 | 1.39× | 1.38× | ||
| Q4 24 | 0.76× | — | ||
| Q3 24 | 1.48× | 1.49× | ||
| Q2 24 | 1.82× | — | ||
| Q1 24 | 1.28× | 1.29× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
PFS
セグメントデータなし
